{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,7]],"date-time":"2026-09-07T11:21:33Z","timestamp":1788780093758,"version":"build-2803163510"},"reference-count":39,"publisher":"Ovid Technologies (Wolters Kluwer Health)","issue":"3","license":[{"start":{"date-parts":[[2021,6,4]],"date-time":"2021-06-04T00:00:00Z","timestamp":1622764800000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/onlinelibrary.wiley.com\/termsAndConditions#vor"},{"start":{"date-parts":[[2021,6,4]],"date-time":"2021-06-04T00:00:00Z","timestamp":1622764800000},"content-version":"tdm","delay-in-days":0,"URL":"http:\/\/doi.wiley.com\/10.1002\/tdm_license_1.1"}],"content-domain":{"domain":["lww.com","ovid.com"],"crossmark-restriction":true},"short-container-title":["Hepatology"],"published-print":{"date-parts":[[2021,9]]},"abstract":"<jats:p>HCV infections have increased in recent years due to injection drug use and the opioid epidemic. Simultaneously, HCV cure has become a reality, with the advent of direct\u2010acting antivirals (DAAs) and expansion of treatment programs. As a result, HCV screening recommendations now include all adults, including pregnant individuals; and many countries have endorsed widespread DAA access as a strategy to achieve HCV eradication. However, almost universally, pregnant individuals have been systematically excluded from HCV clinical research and treatment programs. This omission runs counter to public health strategies focused on elimination of HCV but is consistent with a historical pattern of exclusion of pregnant individuals from research. Our systematic review of publications on HCV treatment with DAAs in pregnancy revealed only one interventional study, which evaluated sofosbuvir\/ledipasvir in 8 pregnant individuals. Given the paucity of research on this issue of great public health importance, we aimed to appraise the current landscape of HCV research\/treatment and analyze the ethical considerations for responsibly including pregnant individuals. We propose that pregnancy may be an opportune time to offer HCV treatment given improved access, motivation, and other health care monitoring occurring in the antenatal period. Moreover, treatment of pregnant individuals may support the goal of eliminating perinatal HCV transmission and overcome the established challenges with transitioning care after delivery. The exclusion of pregnant individuals without justification denies them and their offspring access to potential health benefits, raising justice concerns considering growing data on DAA safety and global efforts to promote equitable and comprehensive HCV eradication. Finally, we propose a path forward for research and treatment programs during pregnancy to help advance the goal of HCV elimination.<\/jats:p>","DOI":"10.1002\/hep.31825","type":"journal-article","created":{"date-parts":[[2021,3,20]],"date-time":"2021-03-20T17:44:05Z","timestamp":1616262245000},"page":"1645-1651","update-policy":"https:\/\/doi.org\/10.1097\/lww.0000000000001000","source":"Crossref","is-referenced-by-count":25,"title":["Responsible Inclusion of Pregnant Individuals in Eradicating HCV"],"prefix":"10.1097","volume":"74","author":[{"ORCID":"https:\/\/orcid.org\/0000-0001-9921-0419","authenticated-orcid":false,"given":"Ravi","family":"Jhaveri","sequence":"first","affiliation":[{"name":"Department of Pediatrics,Northwestern University Feinberg School of Medicine,Chicago,IL"},{"name":"Division of Infectious Diseases,Ann & Robert H. Lurie Children's Hospital of Chicago,Chicago,IL"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lynn M.","family":"Yee","sequence":"additional","affiliation":[{"name":"Division of Maternal Fetal Medicine,Department of Obstetrics and Gynecology,Northwestern University Feinberg School of Medicine,Chicago,IL"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Swati","family":"Antala","sequence":"additional","affiliation":[{"name":"Department of Pediatrics,Northwestern University Feinberg School of Medicine,Chicago,IL"},{"name":"Division of Gastroenterology,Ann & Robert H. Lurie Children's Hospital of Chicago,Chicago,IL"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Margaret","family":"Murphy","sequence":"additional","affiliation":[{"name":"Department of Pediatrics,Northwestern University Feinberg School of Medicine,Chicago,IL"},{"name":"Stanley Manne Children's Research Institute,Ann & Robert H. Lurie Children's Hospital of Chicago,Chicago,IL"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"William A.","family":"Grobman","sequence":"additional","affiliation":[{"name":"Division of Maternal Fetal Medicine,Department of Obstetrics and Gynecology,Northwestern University Feinberg School of Medicine,Chicago,IL"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Seema K.","family":"Shah","sequence":"additional","affiliation":[{"name":"Department of Pediatrics,Northwestern University Feinberg School of Medicine,Chicago,IL"},{"name":"Advanced General Pediatrics,Ann & Robert H. Lurie Children's Hospital of Chicago,Chicago,IL"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"276","published-online":{"date-parts":[[2021,6,4]]},"reference":[{"key":"hep31825-bib-0001-20250824","doi-asserted-by":"crossref","first-page":"399","DOI":"10.15585\/mmwr.mm6914a2","article-title":"Vital signs: newly reported acute and chronic hepatitis C cases\u2014United States, 2009\u20102018","volume":"69","year":"2020","journal-title":"MMWR Morb Mortal Wkly Rep"},{"key":"hep31825-bib-0002-20250824","first-page":"453","article-title":"Increases in hepatitis C virus infection related to injection drug use among persons aged \u226430 years\u2014Kentucky, Tennessee, Virginia, and West Virginia, 2006\u20102012","volume":"64","year":"2015","journal-title":"MMWR Morb Mortal Wkly Rep"},{"key":"hep31825-bib-0003-20250824","doi-asserted-by":"crossref","first-page":"1411","DOI":"10.1093\/cid\/ciu643","article-title":"Emerging epidemic of hepatitis C virus infections among young nonurban persons who inject drugs in the United States, 2006\u20102012","volume":"59","year":"2014","journal-title":"Clin Infect Dis"},{"key":"hep31825-bib-0004-20250824","first-page":"1","article-title":"Recommendations for the identification of chronic hepatitis C virus infection among persons born during 1945\u20101965","volume":"61","year":"2012","journal-title":"MMWR Recomm Rep"},{"key":"hep31825-bib-0005-20250824","doi-asserted-by":"crossref","first-page":"1","DOI":"10.15585\/mmwr.rr6902a1","article-title":"CDC recommendations for hepatitis C screening among adults\u2014United States, 2020","volume":"69","year":"2020","journal-title":"MMWR Recomm Rep"},{"key":"hep31825-bib-0006-20250824","doi-asserted-by":"crossref","first-page":"970","DOI":"10.1001\/jama.2020.1123","article-title":"Screening for hepatitis C virus infection in adolescents and adults: US Preventive Services Task Force recommendation statement","volume":"323","year":"2020","journal-title":"JAMA"},{"key":"hep31825-bib-0007-20250824","doi-asserted-by":"crossref","first-page":"2599","DOI":"10.1056\/NEJMoa1512610","article-title":"Sofosbuvir and velpatasvir for HCV genotype 1, 2, 4, 5, and 6 infection","volume":"373","year":"2015","journal-title":"N Engl J Med"},{"key":"hep31825-bib-0008-20250824","doi-asserted-by":"crossref","first-page":"958","DOI":"10.1016\/S0140-6736(01)06102-5","article-title":"Peginterferon alfa\u20102b plus ribavirin compared with interferon alfa\u20102b plus ribavirin for initial treatment of chronic hepatitis C: a randomised trial","volume":"358","year":"2001","journal-title":"Lancet"},{"key":"hep31825-bib-0009-20250824","doi-asserted-by":"crossref","first-page":"263","DOI":"10.1016\/j.jhep.2017.03.039","article-title":"Glecaprevir and pibrentasvir yield high response rates in patients with HCV genotype 1\u20106 without cirrhosis","volume":"67","year":"2017","journal-title":"J Hepatol"},{"key":"hep31825-bib-0010-20250824","doi-asserted-by":"crossref","first-page":"665","DOI":"10.1016\/j.jhep.2017.06.033","article-title":"Micro\u2010elimination\u2014a path to global elimination of hepatitis C","volume":"67","year":"2017","journal-title":"J Hepatol"},{"key":"hep31825-bib-0014-20250824","doi-asserted-by":"crossref","first-page":"500","DOI":"10.1111\/joim.12740","article-title":"Treatment as prevention for hepatitis C (TraP Hep C)\u2014a nationwide elimination programme in Iceland using direct\u2010acting antiviral agents","volume":"283","year":"2018","journal-title":"J Intern Med"},{"key":"hep31825-bib-0015-20250824","doi-asserted-by":"crossref","first-page":"4330","DOI":"10.3748\/wjg.v24.i38.4330","article-title":"Towards hepatitis C virus elimination: Egyptian experience, achievements and limitations","volume":"24","year":"2018","journal-title":"World J Gastroenterol"},{"key":"hep31825-bib-0018-20250824","doi-asserted-by":"crossref","first-page":"1977","DOI":"10.1001\/jama.2018.15782","article-title":"Alternative state\u2010level financing for hepatitis C treatment\u2014the, \u201cNetflix model.\u201d","volume":"320","year":"2018","journal-title":"JAMA"},{"key":"hep31825-bib-0019-20250824","doi-asserted-by":"crossref","first-page":"362","DOI":"10.5694\/mja2.50584","article-title":"Hepatitis C elimination in Australia: progress and challenges","volume":"212","year":"2020","journal-title":"Med J Aust"},{"key":"hep31825-bib-0020-20250824","doi-asserted-by":"crossref","first-page":"705","DOI":"10.15585\/mmwr.mm6528a2","article-title":"Increased hepatitis C virus (HCV) detection in women of childbearing age and potential risk for vertical transmission\u2014United States and Kentucky, 2011\u20102014","volume":"65","year":"2016","journal-title":"MMWR Morb Mortal Wkly Rep"},{"key":"hep31825-bib-0021-20250824","doi-asserted-by":"crossref","first-page":"775","DOI":"10.7326\/M16-2350","article-title":"Hepatitis C virus infection among reproductive\u2010aged women and children in the United States, 2006 to 2014","volume":"166","year":"2017","journal-title":"Ann Intern Med"},{"key":"hep31825-bib-0022-20250824","doi-asserted-by":"crossref","first-page":"470","DOI":"10.15585\/mmwr.mm6618a3","article-title":"Hepatitis C virus infection among women giving birth\u2014Tennessee and United States, 2009\u20102014","volume":"66","year":"2017","journal-title":"MMWR Morb Mortal Wkly Rep"},{"key":"hep31825-bib-0023-20250824","doi-asserted-by":"crossref","first-page":"1136","DOI":"10.15585\/mmwr.mm6642a3","article-title":"Increased risk for mother\u2010to\u2010infant transmission of hepatitis C virus among Medicaid recipients\u2014Wisconsin, 2011\u20132015","volume":"66","year":"2017","journal-title":"MMWR Morb Mortal Wkly Rep"},{"key":"hep31825-bib-0025-20250824","article-title":"Hepatitis C virus screening among children exposed during pregnancy","volume":"141","year":"2018","journal-title":"Pediatrics"},{"key":"hep31825-bib-0026-20250824","doi-asserted-by":"crossref","first-page":"201","DOI":"10.15585\/mmwr.mm6706a6","article-title":"Notes from the field: underreporting of maternal hepatitis C virus infection status and the need for infant testing\u2014Oregon, 2015","volume":"67","year":"2018","journal-title":"MMWR Morb Mortal Wkly Rep"},{"key":"hep31825-bib-0028-20250824","doi-asserted-by":"crossref","first-page":"e200","DOI":"10.1016\/S2666-5247(20)30062-8","article-title":"Ledipasvir plus sofosbuvir in pregnant women with hepatitis C virus infection: a phase 1 pharmacokinetic study","volume":"1","year":"2020","journal-title":"Lancet Microbe"},{"key":"hep31825-bib-0030-20250824","doi-asserted-by":"crossref","first-page":"5","DOI":"10.3138\/ijfab.1.2.5","article-title":"The second wave: Toward responsible inclusion of pregnant women in research","volume":"1","year":"2008","journal-title":"Int J Fem Approaches Bioeth"},{"key":"hep31825-bib-0031-20250824","doi-asserted-by":"crossref","first-page":"158","DOI":"10.1186\/s12978-017-0431-1","article-title":"The global forum on bioethics in research meeting, \u201cEthics of Research in Pregnancy\u201d: emerging consensus themes and outputs","volume":"14","year":"2017","journal-title":"Reprod Health"},{"key":"hep31825-bib-0032-20250824","doi-asserted-by":"crossref","first-page":"82","DOI":"10.1017\/S0963180107070090","article-title":"Four paradigms of clinical research and research oversight","volume":"16","year":"2007","journal-title":"Camb Q Healthc Ethics"},{"key":"hep31825-bib-0033-20250824","first-page":"367","article-title":"How the CIOMS guidelines contribute to fair inclusion of pregnant women in research","volume":"33","year":"2019","journal-title":"Bioethics"},{"key":"hep31825-bib-0036-20250824","first-page":"175","article-title":"Evolving knowledge of the teratogenicity of medications in human pregnancy","volume":"157C","year":"2011","journal-title":"Am J Med Genet C Semin Med Genet"},{"key":"hep31825-bib-0037-20250824","doi-asserted-by":"crossref","first-page":"26","DOI":"10.1097\/AOG.0000000000003924","article-title":"Protection by exclusion: another missed opportunity to include pregnant women in research during the coronavirus disease 2019 (COVID\u201019) pandemic","volume":"136","year":"2020","journal-title":"Obstet Gynecol"},{"key":"hep31825-bib-0038-20250824","doi-asserted-by":"crossref","first-page":"879","DOI":"10.1093\/cid\/ciaa444","article-title":"Importance of inclusion of pregnant and breastfeeding women in COVID\u201019 therapeutic trials","volume":"71","year":"2020","journal-title":"Clin Infect Dis"},{"key":"hep31825-bib-0039-20250824","doi-asserted-by":"crossref","first-page":"657","DOI":"10.1136\/medethics-2016-103955","article-title":"Vulnerability of pregnant women in clinical research","volume":"43","year":"2017","journal-title":"J Med Ethics"},{"key":"hep31825-bib-0041-20250824","doi-asserted-by":"crossref","first-page":"123","DOI":"10.1186\/s13063-018-2495-9","article-title":"Towards an appropriate framework to facilitate responsible inclusion of pregnant women in drug development programs","volume":"19","year":"2018","journal-title":"Trials"},{"key":"hep31825-bib-0042-20250824","article-title":"Hepatitis C virus (HCV) vertical transmission in 12\u2010month\u2010old infants born to HCV\u2010infected women and assessment of maternal risk factors. Open Forum","volume":"2","year":"2015","journal-title":"Infect Dis"},{"key":"hep31825-bib-0043-20250824","doi-asserted-by":"crossref","first-page":"515","DOI":"10.1016\/S0140-6736(13)62121-2","article-title":"Sofosbuvir and ledipasvir fixed\u2010dose combination with and without ribavirin in treatment\u2010naive and previously treated patients with genotype 1 hepatitis C virus infection (LONESTAR): an open\u2010label, randomised, phase 2 trial","volume":"383","year":"2014","journal-title":"Lancet"},{"key":"hep31825-bib-0044-20250824","doi-asserted-by":"crossref","first-page":"155","DOI":"10.1007\/s11904-018-0386-z","article-title":"Treatment of hepatitis C during pregnancy\u2014weighing the risks and benefits in contrast to HIV","volume":"15","year":"2018","journal-title":"Curr HIV\/AIDS Rep"},{"key":"hep31825-bib-0047-20250824","doi-asserted-by":"crossref","first-page":"116","DOI":"10.1016\/j.ajog.2020.09.024","article-title":"Pregnancy as a \"golden opportunity\" for patient activation and engagement","volume":"224","year":"2021","journal-title":"Am J Obstet Gynecol"},{"key":"hep31825-bib-0048-20250824","doi-asserted-by":"crossref","first-page":"980","DOI":"10.1093\/cid\/ciw026","article-title":"Failure to test and identify perinatally infected children born to hepatitis C virus\u2013infected women","volume":"62","year":"2016","journal-title":"Clin Infect Dis"},{"key":"hep31825-bib-0049-20250824","doi-asserted-by":"crossref","first-page":"34","DOI":"10.1016\/j.jpeds.2018.07.006","article-title":"Perinatal transmission of hepatitis C virus: defining the cascade of care","volume":"203","year":"2018","journal-title":"J Pediatr"},{"key":"hep31825-bib-0050-20250824","article-title":"Hepatitis C testing among perinatally exposed infants","volume":"145","year":"2020","journal-title":"Pediatrics"},{"key":"hep31825-bib-0051-20250824","doi-asserted-by":"crossref","first-page":"289","DOI":"10.1097\/AOG.0000000000003062","article-title":"Short\u2010term effects and long\u2010term cost\u2010effectiveness of universal hepatitis C testing in prenatal care","volume":"133","year":"2019","journal-title":"Obstet Gynecol"},{"key":"hep31825-bib-0052-20250824","doi-asserted-by":"crossref","first-page":"38","DOI":"10.1002\/hast.706","article-title":"Research with pregnant women: new insights on legal decision\u2010making","volume":"47","year":"2017","journal-title":"Hastings Cent Rep"}],"container-title":["Hepatology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/pdf\/10.1002\/hep.31825","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/full-xml\/10.1002\/hep.31825","content-type":"application\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/journals.lww.com\/10.1002\/hep.31825","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,8,24]],"date-time":"2025-08-24T23:10:49Z","timestamp":1756077049000},"score":1,"resource":{"primary":{"URL":"https:\/\/journals.lww.com\/10.1002\/hep.31825"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2021,6,4]]},"references-count":39,"journal-issue":{"issue":"3","published-print":{"date-parts":[[2021]]}},"URL":"https:\/\/doi.org\/10.1002\/hep.31825","relation":{},"ISSN":["0270-9139","1527-3350"],"issn-type":[{"value":"0270-9139","type":"print"},{"value":"1527-3350","type":"electronic"}],"subject":[],"published":{"date-parts":[[2021,6,4]]},"assertion":[{"value":"2020-12-18","name":"received","label":"Received","group":{"name":"publication_history","label":"Publication History"}},{"value":"2021-03-17","name":"accepted","label":"Accepted","group":{"name":"publication_history","label":"Publication History"}}]}}